

Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (casirivimab and imdevimab) versus standard antiviral therapy as antiviral agent against Corona virus 2 infection in hospitalized COVID-19 patients

Ahmed H. Hassan^{*}, Sahar K. Hegazy^{**}, Samar T. Radwan^{***}

^{*} Clinical pharmacy Department, Mansoura University Hospital

^{**} Clinical pharmacy Department, Faculty of Pharmacy, Tanta University

^{***} Rheumatology and Immunology Department, Faculty of medicine, Mansoura University

Abstract

Introduction:

Corona Virus-induced disease – 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of the 2021 year, various advances in pharmacotherapy against COVID-19 have emerged.

Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipravir.

Aim of Study:

To compare the efficacy and safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir, and Favipravir in the COVID-19 patients

Patients and Population:

265 hospitalized COVID-19 patients were used to represent the COVID-19 population and were assigned into three groups in a ratio of (1:2:2) respectively, Group (A) received REGN3048-3051 (Antibodies cocktail (casirivimab and imdevimab)), group (B) received remdesivir, and group (C) received favipravir.

Methods:

The study design is a single-blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are owned by Mansoura University Hospital (MUH) and prescribed by chest diseases lectures of the faculty of medicine-Mansoura University. The duration of the study is about 6 months after ethical approval.

Results and discussion:

Casirivimab and imdevimab achieve less 28-day mortality rate, less mortality at hospital discharge, more negative swab cases, less need for O₂ therapy and IMV, less duration of this need, less hospital and ICU stay, less case progression as presented by lower World Health Organization (WHO) scale and better multi-organ functions as presented by lower

Sequential Organ Function Assessment (SOFA) score than Remdesivir and Favipravir.

Conclusion:

From all of these results, it is concluded that Group A (Casirivimab & imdevimab) has more favorable clinical outcomes than B (remdesivir) & C (favipravir) intervention groups.

Clinical Trial Registration: NCT05502081, 16/08/2022, Clinicaltrials.gov, retrospectively registered

Index Terms (Keywords) – Antivirals; Casirivimab and imdevimab; COVID-19; Favipravir; Remdesivir

I. INTRODUCTION

1.1. COVID-19 overview and classification

COVID-19 is an infectious viral disease caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) that has affected a large number of people all over the world with high mortality rate (Okonji et al., 2021). COVID-19 infection has been classified (NIH, 2021) as: as Mild Illness in which signs and symptoms of COVID-19 exist (e.g., cough, fever, sore throat, headache, loss of taste and smell muscle pain, vomiting, diarrhea) but without dyspnea, shortness of breath, or abnormal chest imaging. Moderate Illness in which evidence of lower respiratory disease exists with an oxygen saturation (SpO₂) $\geq 94\%$ on room air. Severe Illness in which SpO₂ $< 94\%$ on room air, respiratory frequency > 30 breaths/min, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO₂/FiO₂) < 300 mm Hg, or lung infiltrates $> 50\%$. Critical Illness in which respiratory failure, septic shock, and/or multiple organ dysfunctions may occur.

COVID-19 pandemic stimulates research works to find a solution to this crisis from the start of the 2020-year up to now. With the end of the year 2021, various advances in pharmacotherapy against COVID-19 have emerged. (Umakanthan et al., 2021).

1.2. Standard and controversial antivirals used in treatment of COVID-19 (Remdesivir and Favipravir)

Regarding antiviral drugs used in treatment of COVID-19, Remdesivir is a standard antiviral against COVID-19 and has been approved by Food and drug administration (FDA) for treatment of mild, moderate, severe and critical hospitalized COVID-19 patients (Aleem and Kothadia, 2021). Other drugs have shown controversial antiviral activity include: favipravir, ivermectin, nitazoxanide, hydroxychloroquine, ribavirin. Favipravir became a standard antiviral which has been used for treatment of mild and moderate COVID-19 outpatients (de Almeida et al., 2020).

1.3. Advances in immunotherapy for treatment of COVID-19

Recently with the end of 2020, immunotherapy to target virus antigen has developed (Owji et al., 2020). Figure 1 shows two types of immunotherapies include active and passive immunotherapy. Active immunotherapy is to enhance body to produce antibodies against virus as by vaccination. Passive immunotherapy involves administration of products containing antibodies like plasma, or direct administration of prepared antibodies acting specifically against virus (Owji et al., 2020).

In this study, the point of research is antibodies cocktail including REGN3048-3051 (casirivimab and imdevimab). There are three targets for these antibodies to work as antiviral including: antibodies that prevent the virus attachment and entry, antibodies that inhibit the virus replication and transcription, and antibodies that hinder various steps of the immune system response

Table 1 includes various types of antibodies under investigation for treatment of COVID-19 and their targets (Owji et al., 2020).

1.4. Casirivimab and Imdevimab as antibodies cocktail against COVID-19

Antibodies cocktail including REGN3048-3051 (casirivimab and imdevimab) are human monoclonal antibodies that target the spike glycoprotein on surface of viral particles to prevent viral entry into human cells by the angiotensin-converting enzyme 2 (ACE2) receptor (Baum et al., 2020, Hansen et al., 2020), and showed an antiviral activity and needs for further research to prove their efficacy in COVID patients [OB].




Fig.1: Immunization approaches against COVID-19(Owji et al., 2020)

Table 1 shows antibodies candidate against SARS-CoV-2 under investigation by pharmaceutical companies (Owji et al., 2020).

Antibody	Mechanism	Company	Stage of study/identification method
VIR-7831/VIR-7832	-Neutralize highly conserved epitope in s protein -Induce NK-mediated antibody-dependent cell cytotoxicity	VIR biotechnology and GSK	Designed based on S309 (isolated from SARS-Cov patients)
SAB	Anti SARS-CoV-2 fully human polyclonal antibodies	SAB Biotherapeutics	-Antibodies produced in genetically engineered cattle will enter clinical trial by early summer -SAB-301 against MERS passes phase 1 of clinical trial and entered phase II/III
–	Target multiple viral S epitope	ImmunoPrecise	Using B cell Select® and Deep Display® technology
COVID-HIG and COVID-EIG	Hyperimmune polyclonal antibody derived from human plasma or immunized horse	Emergent BioSolutions	Enter clinical trial within 4–5 months
Rcig	Recombinant anti SARS-CoV-2 hyperimmune gammaglobulin, polyclonal antibodies	GigaGen	Preclinical stage- -Aimed for COVID19 hospitalized patients and prophylaxis in high risk individuals

Antibody cocktail including REGN3048-3051	Fully human multivalent antibodies against the spike protein isolated from genetically modified mice or recovered COVID-19 patients	Regeneron	-Phase 1 clinical trial for Middle East Respiratory Syndrome (MERS) completed last year -Clinical trial for SARS-CoV-2 starts by early summer
---	---	-----------	--

II. AIM OF THE STUDY:

To evaluate the efficacy of antibodies cocktail (casirivimab and imdevimab) compared to standard antiviral therapy in reducing 28-day mortality in hospitalized patients with moderate, severe or critical COVID19, as well to examine its safety by monitoring hypersensitivity and infusion related reactions or other significant adverse effects

III. PATIENTS AND POPULATION

265 hospitalized COVID-19 patients are used to represent COVID-19 population and was assigned into 3 groups in a ratio of (1:2:2) respectively, group (A) received REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab)), group (B) received remdesivir, and group (C) received favipravir

Populations in this study are the COVID-19 patients admitted to isolation hospital-Mansoura University. An electronic file containing a written informed consent from included patients will be provided. Paper will not be a tool for providing agreement by the patients or their relatives to avoid transmission of infection

Inclusion criteria include age more than 12 years old, weight not less than 40 kg, moderate, severe or critical COVID-19 disease as defined by WHO, and PCR- confirmed patients to be Positive before inclusion. Exclusion criteria include history of hypersensitivity or infusion related reactions after administration of monoclonal antibodies, prior use of standard antiviral therapy (remdesivir or favipravir), Current use of controversial antiviral therapy (ivermectin, hydroxychloroquine, oseltamivir, nitazoxanide, ribavirin,

lopinavir/ritonavir, daclatasvir, sofosbuvir, semipirvir, acyclovir, azithromycin), and patients expected to die within 48 hours.

IV. INTERVENTIONS

Population included in this study will be assigned into 3 groups with 1:2:2 ratios to receive either antibodies cocktail or standard antiviral therapy (remdesivir, favipravir) as shown in table2 and figures 2,3.

Group A patients will receive REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab)) in low-dose regimen 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes.

Group B patients will receive Remdesivir :
Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes
Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes

Group C patients will receive Favipravir :
Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours
Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours

Patients will be received standard of care by Physicians, Clinical pharmacist , Nurses and as guided by Egyptian COVID-19 treatment protocol.

Table 2 : The three intervention groups of the study

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	A	53	20.0	20.0	20.0
	B	106	40.0	40.0	60.0
	C	106	40.0	40.0	100.0
	Total	265	100.0	100.0	




Figure 2: Assignment of the included COVID cases at their groups.




Figure 3: Frequency of interventions in included patients

V. METHOD

The type of this study is single blind non-RCT and is considered a Phase IV Clinical trial (post-marketing study) to report efficacy and safety of new medicine.

We use PubMed search tool to find clinical studies that performed to test efficacy and safety of developed immunotherapy in treatment of COVID-19 with about 4,000 results with focusing on antibodies developed as antiviral against COVID-19 obtaining only 70 results from which REGN-COV2, a Neutralizing Antibody Cocktail is selected with its only one clinical study up to now (REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19) which is published in New England Journal of Medicine on January 21, 2021.

Another resource used to obtain data is Fact Sheet for Health Care Providers- EUA OF casirivimab and imdevimab which provides clinical data about the use of this antibodies cocktail. Endnote citation software is used for citation of references.

VI. OUTCOMES

Parameters that will be assessed during hospitalization at day 0(baseline), day 3, 7, 14, 28 include:

- C-reactive protein (CRP)
- ferritin
- lactate dehydrogenase (LDH)
- D-dimer
- serum creatinine (S.Cr) and estimated creatinine clearance (CrCl)
- alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, bilirubin

Clinical outcomes measured before & during intervention

1) Primary outcomes

- 1- 28-days mortality rate (efficacy).
- 2-PCR test results at end of hospital visit (efficacy).
- 3-percentage of patients who developed infusion related or hypersensitivity reactions during and after the end of drug infusion and reporting of any Serious and unexpected adverse events may occur that have not been previously reported with REGEN-COV use that may cause drug discontinuation (Safety).

2) Secondary outcomes

- 1-Need for invasive mechanical ventilation (IMV)
- 2- Invasive mechanical ventilation and oxygen support duration (days).
- 3- Time to clinical improvement(Garibaldi et al., 2021) (defined as 2 points reduction in the WHO disease ordinal progression scale(Plaçais et al., 2022) or discharge, whatever happens first)
- 4- ICU and hospitalization length of stay (days).
- 5- SOFA score(Yang et al., 2021) on day 0,3,7,14, and 28.
- 6- COVID19 WHO disease progression score(Plaçais et al.,

2022) from day 0 to day 28.

7- Inflammatory markers including CRP, ferritin, LDH

8- liver and kidney functions

In addition to clinical outcomes measured before and during intervention, Vital signs, glasgow coma score (GCS),complete blood count (CBC), arterial blood gas (ABG) and prothrombin time (PT) is observed daily and recorded at day0.patients' characteristics(age,gender) and relevant medical and medication history and current COVID-19 treatment drugs will be recorded on admission

Duration of research will be about 6 months from Novmber 2021 to April 2022

VII. Statistical analysis and Sample Size

Statistical analysis

Intention-to-treat strategy will be used in this study. Statistical analysis will be achieved with SPSS, version 26.

Categorical variables will be presented as proportion and percent. Continuous variables will be presented as mean (standard deviation) for parametric data or as a median (25th-75th percentile) for non-parametric data.

Regarding baseline characteristics, Kruskal-Wallis or ANOVA test (depending on type of data and the continous data distrubation (normal or not)) will be used to compare these characteristics between the study groups. We will report the P-value for our statistical tests with level of statistical significance will be P-value ≤ 0.05 .

In case of existiiing differences in some baseline characteristics, logistic regression will be performed. This allows studying the effect of these variables on the primary outcomes of the study to exclude the effect of these confounding vaiables and to ensure the effect on the outcomes is due to interventions.

we will compare the 28-day all- , Regarding the outcomes result of PCR test at hospital discharge and ,cause mortality rate incidence of infusion related or hypersensitivity reactions during and after the end of drug infusion (primary outcome) using the .Kruskal-Wallis test with reporting the P-value icu ,While the secondary outcomes (hospital stay duration stay duration and others) are compared using Kruskal-Wallis or ANOVA test depending on type of data and the continous data distrubation (normal or not).

Sample Size

A total sample sizes of 246 patients would achieve at least 80 % power to detect a risk difference of 0.2 (20%) in the 28-day

all-cause mortality (primary outcome) with a significance level (α) of 0.05 and 95% confidence level using the ANOVA or Kruskal-Wallis test of independent proportion in G*Power software. To compensate for the estimated loss-to-follow-up and increase the study power, we will increase the sample size in both remdesivir and favipravir groups to be 106 patients compared to 53 patients in Antibodies cocktail Group As Antibodies cocktail product is available for only about 50 COVID-19 patients. In addition, the ratio (1:2:2) is the closest to reality according to number of patients who receive each drug.

The mortality data was estimated from the average mortality in August, September, and October 2021 at the Mansoura University Isolation Hospital among all hospitalized patients. Mortality rate is found to be about 360 cases in these 3 months (120 cases / month). The online system has been used to obtain mortality rate in these three months.

Table 3: the Significance of differences in baseline characteristics between the three groups

Variables	intervention				P-values*
	Casirivimab /Imdevimab (A)	Remdesivir (B)	Favipravir (C)		
Age	58.34±16.096	59.30±15.985	65.02±14.261		0.006
B & C					0.07
A & C					0.07
A & B					0.63
Gender	Male	24/53	42/106	61/106	0.03
	Female	29/53	64/106	45/106	
B & C					0.09
A & C					0.145
A & B					0.501
Number of co-morbidity	0	10/53	32/106	22/106	0.022
	1	16/53	27/106	19/106	
B & C					0.024
A & C					0.024
A & B					0.024

es	2	14/53	28/106	33/106	
	3	11/53	16/106	18/106	
	4	2/53	2/106	10/106	
	5	0/53	1/106	3/106	
	6	0/53	0/106	1/106	
B & C					0.06
A & C					0.320
A & B					0.207
Method of diagnosis	Symptoms only	0/53	0/106	0/106	1
	Labs & Radiology	0/53	0/106	0/106	
	PCR confirmed	53/53	106/106	106/106	
B & C					NA
A & C					NA
A & B					NA
sever	moder	18/53	20/106	20/106	0.024

The current admission rate at the Mansoura University – Isolation Hospital is 250 cases per month on average; our needed sample is about 250 cases.

VIII. RESULTS

After statistical analysis using SPSS software, all continuous data shows no normal distribution. So Kruskal-Wallis Test is used to compare non normally distributed continuous, categorical and nominal variables between the three groups.

8.1. Regarding baseline characteristics

Table 3 shows the significance of difference between the three groups and also includes a pairwise comparison between every two groups in baseline characteristics if they show statistically significant difference between the three groups. Figures (4-23) show distributions and frequencies of baseline characteristics between the three groups.

ty of COVID	ate					A & B				0.075		
	sever	27/53	60/106	53/106		Fluoroquinolones use	Yes	41/53	92/106	95/106	0.106	
	critical	8/53	26/106	33/106			No	12/53	14/106	11/106		
B & C					0.475	B & C					NA	
A & C					0.07	A & C					NA	
A & B					0.035	A & B					NA	
WHO clinical progression score	3	0/53	1/106	0/106	0.004	3rd & 4th generation cephalosporin use	Yes	39/53	86/106	83/106	0.551	
	4	15/53	5/106	10/106			No	14/53	20/106	23/106		
	5	35/53	100/106	96/106		B & C	B & C					NA
	6	3/53	0/106	0/106			A & C					NA
B & C					0.305	A & B					NA	
A & C					0.014	Carbapenems use					0.168	
A & B					0.001	Piperacillin/tazobactam use	Yes	.10/53	.32/106	.22/106		
Number of symptoms	2	4/53	2/106	2/106	0.001		B & C	No	43/53	74/106	84/106	
	3	13/53	6/106	4/106		B & C					NA	
	4	32/53	97/106	97/106		A & C					NA	
	5	4/53	1/106	3/106		A & B					NA	
B & C					0.482	Piperacillin/tazobactam use					1	
A & C					0	B & C	Yes	0/53	0/106	0/106		
A & B					0.003		B & C					NA
Antibiotics use	Yes	53/53	106/106	106/106	1	A & C					NA	
	No	0/53	0/106	0/106		A & B					NA	
B & C					0.102	Amoxicillin/clavulanate use					0.472	
A & C					0.002	B & C	Yes	0/53	0/106	0/106		
A & B					0.075		B & C					NA
Macrolide use	Yes	8/53	8/106	2/106	0.007	A & C					NA	
	No	45/53	98/106	104/106		A & B					NA	
B & C					0.102	Amoxicillin/clavulanate use					0.472	
A & C					0.002	B & C						NA

A & B						NA	A & C						0.005
Cotrimoxazole use						1	A & B						0.262
Yes		0/53	0/106	0/106			Steroids use						0.002
No		53/53	106/106	106/106		Yes		45/53	105/106	98/106			
B & C						NA	No		8/53	1/106	8/106		
A & C						NA	B & C						0.50
A & B						NA	A & C						0.068
Linezolid use						0.115	A & B						0.001
Yes		5/53	12/106	4/106			additive therapy use		Yes	51/53	106/106	105/106	
No		48/53	94/106	102/106		B & C						NA	
B & C						NA	No		2/53	0/106	1/106		
A & C						NA	A & C						NA
A & B						NA	A & B						NA
Teicoplanin use						0.365	Paracetamol use		yes	50/53	105/106	106/106	
Yes		1/53	0/106	2/106			no		3/53	1/106	0/106		
No		52/53	106/106	104/106		B & C						0.574	
B & C						NA	A & C						0.006
A & C						NA	A & B						0.022
A & B						NA	Zinc use		Yes	4/53	0/106	1/106	
Anticoagulant use						0.411	No		49/53	106/106	105/106		
Yes		49/53	101/106	96/106			B & C						0.614
No		4/53	5/106	10/106		A & C						0.004	
B & C						NA	A & B						0.001
A & C						NA	Acetylcysteine use		Yes	52/53	106/106	106/106	
A & B						NA	No		1/53	0/106	0/106		
Dose of anticoagulant						0.088	B & C						NA
Prophylactic		39/53	80/106	81/106			A & C						0.004
Therapeutic		14/53	26/106	25/106		A & B						0.001	
B & C						NA	Acetylcysteine use						0.135
A & C						NA	Yes		52/53	106/106	106/106		
A & B						NA	No		1/53	0/106	0/106		
Antiplatelet use						0.012	B & C						NA
Yes		5/53	6/106	0			A & C						NA
No		48/53	100/106	106/106		A & B						0.039	
B & C						0.039							

A & B					NA	A & B				0.0	
Lactoferrin use	Yes	1/53	0/106	0/106	0.1	HFNC⁽⁴⁾ use	Yes	5/53	22/106	18/106	0.2
	No	52/53	106/106	106/106	35		No	48/53	84/106	88/106	0.2
B & C					NA	B & C					NA
A & C					NA	A & C					NA
A & B					NA	A & B					NA
vitamin C use	Yes	4/53	7/106	1/106	0.0	CPAP⁽⁵⁾ use	Yes	4/53	39/106	36/106	0
	No	49/53	99/106	105/106	70		No	49/53	67/106	70/106	0
B & C					NA	B & C					0.6
A & C					NA	A & C					0.0
A & B					NA	A & B					0.0
O2 therapy use	Yes	37/53	99/106	102/106	0	IMV⁽⁶⁾ use	Yes	1/53	29/106	29/106	0
	No	16/53	7/106	4/106	0		No	52/53	77/106	77/106	0
B & C					0.4	B & C					1
A & C					0	A & C					0
A & B					0	A & B					0
NP⁽¹⁾ use	Yes	18/53	35/106	39/106	0.8	Vasopressor use	Yes	0/53	23/106	18/106	0.0
	No	35/53	71/106	67/106	4		No	53/53	83/106	88/106	0.2
B & C					NA	B & C					1
A & C					NA	A & C					0.0
A & B					NA	A & B					0.0
SFM⁽²⁾ use	Yes	30/53	82/106	87/106	0.0	Prone positioning	Yes	0/53	5/106	9/106	0.7
	No	23/53	24/106	19/106	0.2		No	53/53	101/106	97/106	0.5
B & C					0.4	B & C					NA
A & C					0	A & C					NA
A & B					0.0	A & B					NA
MR⁽³⁾ use	Yes	8/53	33/106	14/106	0.0	Heart rate		82.40±1	85.70±1	87.02±	0.3
	No	45/53	73/106	92/106	0.3	B & C		2.443	6.072	16.798	0.45
B & C					0.0	B & C					NA
A & C					0.7	A & C					NA
A & B					0.83	A & B					NA

A & C				NA	A & B				NA
A & B				NA	Albumin	3.1774± 0.461	3.1715± 0.480	3.1021 ±0.512	0.6 59
Respiratory rate	24.25±3 .246	25.40±5 .580	24.72± 5.012	0.6 52	B & C				NA
B & C				NA	A & C				NA
A & C				NA	A & B				NA
A & B				NA	PT ⁽¹⁰⁾	14.575± 1.680	15.338± 1.997	15.690 ±2.476	0.0 02
Body temperature	36.951± 0.492	36.938± 0.456	36.906 ±1.183	0.2 88	B & C				0.3 75
B & C				NA	A & C				0
A & C				NA	A & B				0.0 05
A & B				NA	INR ⁽¹¹⁾	1.2625± 0.201	1.3436± 0.239	1.3868 ±0.296	0.0 03
O2 saturation on O2 therapy	96.26±2 .391	95.86±3 .795	96.01± 3.130	0.9 42	B & C				0.2 84
B & C				NA	A & C				0.0 01
A & C				NA	A & B				0.0 13
A & B				NA	S.Cr ⁽¹²⁾	1.2092± 1.355	1.0999± 0.924	1.8807 ±1.912	0 0
O2 saturation on RA ⁽⁷⁾	92.36±4 .816	87.62±7 .171	88.35± 7.006	0 48	B & C				0
B & C				0.4 48	A & C				0
A & C				0	A & B				0.5 57
A & B				0	TLC ⁽¹³⁾	8.6934± 4.129	8.4562± 5.044	11.026 8±9.40	0.0 18
AST ⁽⁸⁾	45.62±3 8.619	52.95±3 5.490	54.52± 67.856	0.1 08	B & C				0.0 05
B & C				NA	A & C				0.1 08
A & C				NA	A & B				0.5 05
A & B				NA	Lymphocyte	0.9658± 0.521	0.9123± 0.429	1.4834 ±5.620	0.7 76
ALT ⁽⁹⁾	33.34±2 7.166	33.27±2 2.826	42.79± 77.372	0.6 0	B & C				NA
B & C				NA	A & C				NA
A & C				NA	A & B				NA
A & B				NA	Bilirubin	0.5472± 0.299	0.6228± 0.790	0.7327 ±0.692	0.7 0
Bilirubin	0.5472± 0.299	0.6228± 0.790	0.7327 ±0.692	0.7 0	B & C				NA
B & C				NA	A & C				NA
A & C				NA					

A & C				NA					
A & B				NA					
Hemoglobin	12.5958 ±1.58	12.4416 ±2.07	11.949 4±2.54	0.1 43					
B & C				NA					
A & C				NA					
A & B				NA					
Hematocrit	39.317± 6.045	36.975± 5.586	35.259 ±8.559	0.0 03					
B & C				0.1 06					
A & C				0.0 01					
A & B				0.0 33					
Platelets	234.913 ±91.5	211.613 ±92.3	217.59 1±122	0.2 30					
B & C				NA					
A & C				NA					
A & B				NA					
LDH⁽¹⁴⁾	413.06± 294.784	389.81± 222.668	378.50 ±250.1 83	0.4 66					
B & C				NA					
A & C				NA					
A & B				NA					
CK⁽¹⁵⁾	185.96± 207.6	228.07± 367.1	232.75 ±287	0.1 09					
B & C				NA					
A & C				NA					
A & B				NA					
D-dimer	0.6189± 0.493	0.1433± 0.227	0.2915 ±0.385	0					
B & C				0.0 05					
A & C				0					
A & B				0					
CRP⁽¹⁶⁾	61.566±	61.292±	95.513	0.1					
						39.71	35.3	±157.8	14
B & C				NA					
A & C				NA					
A & B				NA					
Ferritin	442.34± 190.4	418.06± 193.8	1158.4 ±6953	0.2 30					
B & C				NA					
A & C				NA					
A & B				NA					
Sodium level	146.472 ±30.7	145.243 ±20	144.31 5±18.5	0.2 27					
B & C				NA					
A & C				NA					
A & B				NA					
POTASSIUM level	3.6228± 0.514	3.4701± 0.674	3.7903 ±0.829	0.0 09					
B & C				0.0 03					
A & C				0.6 48					
A & B				0.5 2					
PaO₂⁽¹⁷⁾	77.868± 41.79	56.432± 35.30	63.294 ±39.45	0.0 05					
B & C				0.2 52					
A & C				0.2 0					
A & B				0.0 01					
PaCO₂⁽¹⁸⁾	36.689± 12.59	37.325± 14.60	37.603 ±12.08	0.8 91					
B & C				NA					
A & C				NA					
A & B				NA					
PaO₂/FiO₂⁽¹⁹⁾	233.505 7±207	156.735 8±171	164.14 2±138	0.0 1					
B & C				0.1					

				36	
A & C				0.69	
A & B				0.002	
GCS⁽²⁰⁾	4	0	2	0	0.003
	6	0	1	0	
	8	0	0	1	
	9	0	0	1	
	10	0	2	8	
	13	0	0	3	
	14	1	4	7	
	15	52	97	86	
	4	0	2	0	
B & C				0.019	
A & C				0.001	
A & B				0.202	
SOF A⁽²¹⁾	0	11	2	1	0
	1	1	1	4	
	2	3	9	3	
	3	12	25	17	
	4	17	36	28	
	5	7	18	17	

6	0	6	13	
7	2	4	9	
8	0	3	7	
9	0	1	3	
10	0	1	3	
14	0	0	1	
B & C				0.003
A & C				0
A & B				0.007

*P-value less than 0.05 is considered a statistically significant difference

(1) Nasal Prongs, (2) Simple Face Mask, (3) Mask Reservoir, (4) High Flow Nasal Cannula,

(5) Continuous Positive Airway Pressure, (6) Invasive Mechanical Ventilation, (7) Room Air,

(8) Aspartate Aminotransferase, (9) Alanine aminotransferase, (10) Prothrombin Time,

(11) International Normalized Ratio, (12) Serum Creatinine, (13) Total Leukocytic Count,

(14) Lactate Dehydrogenase, (15) Creatine Kinase, (16) C - reactive protein, (17) Arterial Saturation pressure of Oxygen, (18) Arterial pressure of carbon dioxide, (19) a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen, (20) Glasgow Coma Score, (21) Sequential Organ Function Assessment.

8.1.1. Age

There is statistically significant difference between A-C & B-C and statistically non-significant difference between A-B.




Figure 4: Frequency of Age in included patients




Figure 5: Distribution of Age across the three groups

8.1.2. Gender

There is a statistically significant difference between B-C and a statistically non-significant difference between A-B & A-C.

8.1.3. Number of comorbidities

There is a statistically significant difference between B-C and a statistically non-significant difference between A-B & A-C.




Figure 6: Frequency of co-morbidities number in included patients




Figure 7: Distribution of comorbidities number across the three groups

8.1.4. Method of diagnosis

There is a statistically non-significant difference between the three groups





Figure 8: Distribution of Method of diagnosis across the three groups

Figure 10: Distribution of COVID-19 severity across the three groups

8.1.5. Severity of COVID-19

There is a statistically significant difference between A-B & A-C and a statistically non-significant difference between C-B. There are statistically significant less severe cases in group A than groups B & C. Frequency of COVID severity in included COVID patients is presented in figure 9.

8.1.6. WHO clinical progression scale

There is a statistically significant difference between A-B & A-C and a statistically non-significant difference between C-B. WHO scale is statistically significantly lower in group A than groups B & C.

8.1.7. Number of symptoms

There is a statistically significant difference between A-B & A-C and a statistically non-significant difference between C-B.





Figure 9: Frequency of COVID severity in included COVID-19 patients

Figure 11: Frequency of number of symptoms in included patients

8.1.8. Antibiotics use

In general, there is statistically a non-significant difference between the three groups in antibiotics use. There is only a statistically significant difference between A-C in macrolides (azithromycin & clarithromycin) uses.

8.1.9. Anticoagulants use (enoxaparin, heparin, and rivaroxaban)

There is a statistically non-significant difference between the three groups in anticoagulant use whether in prophylactic or therapeutic dose.

8.1.10. Antiplatelet use (aspirin, clopidogrel)

There is a statistically significant difference between A-C and a statistically non-significant difference between A-B & C-B.

8.1.11. Steroids use (dexamethasone, prednisolone and methylprednisolone)

There is a statistically significant difference between A-B and a statistically non-significant difference between A-C & C-B.

8.1.12. Additive therapy uses (paracetamol, vitamin C, zinc, acetyl cysteine, lactoferrin)

In general; there is statistically non-significant difference between the three groups in additive therapy use. There is only a statistically significant difference between A-C in paracetamol and zinc use & A-B in zinc use.

8.1.13. Oxygen therapy use

In general, there is a statistically significant difference between A-B & A-C and statistically non-significant difference between C-B. There is a statistically non-significant difference between the three groups in nasal prongs and HFNC use.

There is statistically significant difference between A-B & A-C in simple face mask (SFM), Continuous Positive Airway Pressure (CPAP) or Non-Invasive Ventilation (NIV) and IMV use.

There is a statistically significant difference between B-C in mask reservoir (MR) use.

8.1.14. Vasopressor use

There is a statistically significant difference between A-B & A-C in vasopressor use and a statistically non-significant difference between C-B. Use of vasopressors in group A is statistically significantly less than groups B & C.

8.1.15. Prone positioning

There is a statistically nonsignificant difference between the three groups.

8.1.16. Vital signs

There is a statistically non-significant difference between the three groups in heart rate, respiratory rate and temperature.

8.1.17. Oxygen saturation

There is a statistically non-significant difference between the three groups in O₂ saturation on O₂ therapy. But a statistically significant difference exists between A-B & A-C in O₂ saturation on Room air (RA).




Figure 12: Distribution O₂ saturation (on O₂ therapy) across the three groups




Figure 13: Distribution of O2 saturation (on RA) across the three groups

8.1.18. Liver function tests

There is a statistically non-significant difference between the three groups in liver enzymes (AST & ALT), bilirubin, and albumin levels

8.1.19. Coagulation profile

There is a statistically significant difference between A-B & A-C in PT and INR.




Figure 14: Distribution of PT across the three groups




Figure 15: Distribution of INR across the three groups

8.1.20. Kidney function test

There is a statistically significant difference between A-C & B-C in serum creatinine.




Figure 16: Distribution of S.Cr across the three groups.

8.1.21. Inflammatory markers

There is a statistically non-significant difference between the three groups in CK, LDH, Ferritin and CRP levels
 There is a statistically significant difference between the three groups in D-dimer.




Figure 17: Distribution of D-dimer across the three groups.




Figure 19: Distribution of hematocrit across the three groups

8.1.22. Blood picture

There is a statistically significant difference between B-C in TLC and A-B & A-C in haematocrit.

There is a statistically non-significant difference between the three groups in lymphocytic counts, hemoglobin and platelets.

8.1.23. Electrolytes

There is a statistically non-significant difference between the three groups in sodium level. There is a statistically significant difference between B-C in Potassium level.




Figure 18: Distribution of TLC across the three groups




Figure 20: Distribution of Potassium level across the three groups

8.1.24. Blood gases

There is a statistically significant difference between A-B & A-C in PaO₂ and between A-B in PaO₂/FiO₂. There is a statistically non-significant difference between the three groups in PaCO₂.




Figure 21: Distribution of PaO₂ level across the three groups




Figure 22: Distribution of PaO₂/FiO₂ across the three groups

8.1.25. Consciousness level

There is a statistically significant difference between A-C & B-C in GCS and statistically non-significant difference between A-B.

8.1.26. Multi-Organ Functions Assessment

There is a statistically significant difference between the three groups in SOFA score.




Figure 23: Distribution of SOFA score across the three groups

8.1.27. Regression analysis

Regression analysis is performed to explore the effect of baseline characteristics (that show a statistically significant difference between the three groups) on the outcomes of the study and the possibility of existence of confounding variables as shown in table 4.

Table 4: the best regression model for studying the effects of confounding variables on 28-day mortality

	Unstandardized Coefficients		Standardized Coefficients		t
	B	Std. Error	Beta	Std. Error	
(Constant)	.806	1.297			.621
age	.003	.001	.098	.053	1.835
gender	.029	.044	.038	.058	.652
No of co-morbidities	-.002	.015	-.007	.048	-.144
Severity of COVID	-.004	.036	-.007	.059	-.123
WHO clinical progression score	.024	.084	.021	.071	.288
No of symptoms	.029	.033	.049	.057	.854
macrolide	-.030	.083	-.027	.074	-.362

fluoroquinolones	.001	.068	.001	.073	.020	HR	.000	.001	-.008	.049	-1.160
						RR	.006	.004	.066	.049	1.328
cephalosporins	.046	.071	.052	.081	.646	Temp	-.042	.024	-.073	.042	-1.744
carbapenems	.057	.070	.065	.080	.818	O2sat on O2	.002	.007	.014	.057	.250
Amoxicillin/clavulanate	-.191	.398	-.019	.039	-.479	O2sat on RA	-.001	.004	-.023	.061	-.370
						AST	.000	.001	.046	.085	.539
linezolid	-.007	.072	-.006	.058	-.097	ALT	.000	.001	.040	.078	.506
teicoplanin	-.201	.316	-.028	.044	-.636	Bilirubin	.064	.036	.094	.053	1.789
Other Antibiotics	-.029	.105	-.012	.043	-.274	albumin	-.046	.042	-.056	.051	-1.102
						PT	.001	.084	.007	.432	.017
Anticoagulant	-.102	.099	-.069	.067	-1.033	INR	-.087	.696	-.054	.431	-.125
Prophylaxis/therapeutic	-.014	.048	-.019	.063	-.298	S.Cr	.030	.017	.113	.063	1.799
						CK	1.555E-5	.000	.012	.047	.249
antiplatelet	-.028	.083	-.020	.060	-.340	TLC	-.008	.005	-.116	.071	-1.629
steroids	-.044	.078	-.036	.065	-.561	Lymphocyte	.022	.009	.125	.054	2.317
Additive therapy	.096	.120	.041	.051	.803	Hb	.021	.023	.102	.115	.889
Paracetamol	-.045	.095	-.024	.050	-.475	Haematocrit	-.004	.007	-.066	.118	-.557
zinc	-.101	.084	-.059	.049	-1.210	PLT	.000	.000	.047	.055	.860
acetyl cysteine	-.027	.176	-.008	.052	-.151	LDH	.000	.000	.080	.063	1.283
Lactoferrin	.312	.237	.092	.070	1.315	D-dimer	.064	.047	.083	.061	1.356
Vitamin C	.044	.072	.031	.050	.615	CRP	9.424E-5	.000	.017	.043	.403
O2 therapy need	.053	.107	.038	.078	.492	Ferritin	1.616E-6	.000	.011	.042	.270
Nasal prongs use	-.004	.043	-.005	.055	-.083	sodium	-.001	.001	-.059	.057	-1.044
FM use	.040	.053	.046	.060	.764	POTASSIUM	.004	.032	.007	.053	.133
MR use	-.027	.050	-.029	.054	-.538	PaO2	-.002	.001	-.191	.067	-2.841
HFNC use	.004	.050	.003	.048	.071	PaCO2	-.005	.002	-.149	.052	-2.852
CPAP	.003	.092	.004	.101	.035	PaO2/Fio2	.001	.000	.175	.065	2.695
NIV need	.271	.103	.284	.107	2.639	GCS	.022	.015	.073	.048	1.505
IMV need	.549	.091	.507	.084	6.042	SOFA	.012	.018	.050	.077	.650
vasopressor	.054	.093	.042	.072	.579						.563
Prone position	-.183	.105	-.080	.046	-1.740						.084

8.2. Regarding outcomes of the study after intervention in the three groups

Table 5 shows the significance of difference between the three groups and also includes a pairwise comparison between every two groups in clinical outcomes if they show statistically significant difference between the three groups. Figures (24-78) show the distributions and frequencies of these outcomes across the three groups.

Table 5: the Significance of differences in baseline characteristics between the three groups

Variables	intervention			
	Casirivimab /Imdevimab (A)	Remd -esivir (B)	Favip -ravir (C)	P- value s*
AST on day 3	48.53±6 0.487	48.67 ±41.1 28	43.93 ±36.4 97	0.412
B & C				NA
A & C				NA
A & B				NA
AST on day 7	41.77±3 2.465	35.26 ±20.0 89	41.35 ±39.7 8	0.687
B & C				NA
A & C				NA
A & B				NA
AST on day 14	26.75±1 8.118	22.79 ±13.3 19	30.19 ±16.8 02	0.278
B & C				NA
A & C				NA
A & B				NA
AST on day 28		31±11 .605	27±0	1
B & C				NA
ALT at day 3	33.62±3 4.535	36.46 ±32.5 85	36.16 ±49.8 6	0.298
B & C				NA
A & C				NA
A & B				NA
ALT on day 7	26±18.6 04	30.54 ±23.0 62	33.90 ±33.5 8	0.574
B & C				NA

A & C				NA
A & B				NA
ALT on day 14	15.75±4 .856	22.42 ±15.7 88	35.38 ±17.5 5	0.017
B & C				0.01
A & C				0.041
A & B				0.616
ALT on day 28		71.75 ±57	39.50 ±13.4	1
B & C				NA
Bilirubin at day 3	0.4793± 0.255	0.6457 ±0.65 4	0.705 3±0.8 6	0.68
B & C				NA
A & C				NA
A & B				NA
Bilirubin at day 7	0.3717± 0.221	0.6575 ±0.69 9	0.888 6±1.5 4	0
B & C				0.208
A & C				0
A & B				0.001
Bilirubin at day 14	0.3625± 0.110	0.494 ±0.22 29	0.688 8±0.3 7	0.088
B & C				NA
A & C				NA
A & B				NA
Bilirubin on day 28		0.41± 0.1437 6	1.67± 0	0.157
B & C				NA
Albumin on day 3	3.157±0 .3858	2.947 ±0.45 07	2.854 ±0.50 4	0.015
B & C				0.232
A & C				0.004

A & B				0.054
Albumin on day 7	2.98±0.4073	2.77±0.4837	2.644±0.489	0.006
B & C				0.151
A & C				0.001
A & B				0.035
Albumin on day 14	3.425±0.2872	2.82±0.4184	2.813±0.368	0.037
B & C				0.997
A & C				0.016
A & B				0.014
Albumin on day 28		2.575±0.3304	2.7±0	0.48
B & C				NA
Platelets on day 3	271.64±97.62	253.425±105	226.35±116.2	0.047
B & C				0.04
A & C				0.036
A & B				0.67
Platelets on day 7	268.829±93.9	243.514±116.2	212.76±123.2	0.015
B & C				0.027
A & C				0.008
A & B				0.38
Platelets on day 14	248±136.48	216.95±126.3	215.63±126.3	0.814
B & C				NA
A & C				NA
A & B				NA
Platelets on day 28		246.75±113	15±0	0.157
B & C				NA

S.Cr at day 3	1.0769±0.941	0.9546±0.865	1.6568±1.776	0
B & C				0
A & C				0
A & B				0.971
S.Cr at day 7	0.9674±0.752	0.9952±0.987	1.6541±1.9	0.001
B & C				0
A & C				0.017
A & B				0.525
S.Cr at day 14	0.775±0.221	0.6316±0.152	1.45±1.7753	0.007
B & C				0.002
A & C				0.452
A & B				0.237
S.Cr at day 28		0.525±0.1708	1.2±0	0.157
B & C				NA
CRP at day 3	33.87±31.44	52.61±37.719	64.1±63.035	0.002
B & C				0.557
A & C				0.001
A & B				0.004
CRP at day 7	14.06±14.548	47.43±52.631	65.73±90.34	0
B & C				0.891
A & C				0
A & B				0
CRP on day 14	7.5±5.745	37.05±55.395	39.31±54.77	0.516
B & C				NA

A & C				NA
A & B				NA
CRP on day 28		39±38 .419	96±0	0.264
B & C				NA
D-dimer on day 3	0.244±0 .2211	0.23± 0.3321	0.29± 0.384 5	0.219
B & C				NA
A & C				NA
A & B				NA
D-dimer on day 7	0.109±0 .1483	0.319 ±0.50 17	0.425± 0.5678	0.015
B & C				0.223
A & C				0.004
A & B				0.05
D-dimer on day 14	0.05±0. 10	0.41± 0.5999	0.313 ±0.46 1	0.423
B & C				NA
A & C				NA
A & B				NA
D-dimer on day 28		0.40± 0.80	0.40± 0	0.429
B & C				NA
CK on day 3	142.2±1 35.12	197.94 ±342. 1	181.4 5±166	0.089
B & C				NA
A & C				NA
A & B				NA
CK on day 7	126.743 ±112	211.9 ±420. 23	175.9 9±155	0.222
B & C				NA
A & C				NA

A & B				NA
CK on day 14	49.5±30 .116	122.89 ±93.25 9	142.7 5±176	0.252
B & C				NA
A & C				NA
A & B				NA
CK on day 28		119.22 ±88.2 1	134.2 5±113	0.157
B & C				NA
LDH on day 3	351.27± 258.57	404.45 ±214.9 2	354.7 ±204. 2	0.01
B & C				0.06
A & C				0.156
A & B				0.003
LDH on day 7	271.4±1 65.99	371.37 ±196. 2	349.6 8±201	0.007
B & C				0.382
A & C				0.017
A & B				0.002
LDH on day 14	379.75± 313.9	360.89 ±244. 8	306.8 8±266	0.457
B & C				NA
A & C				NA
A & B				NA
LDH on day 28		314.5 ±108. 99	270±0	0.48
B & C				NA
Ferritin on day 3	393.04± 170.2	427.25 ±194. 8	1110± 6784. 6	0.106
B & C				NA
A & C				NA

A & B				NA	
Ferritin on day 7	368.42±167.8	450.37±247.6	1433±8174	0.01	
B & C				0.605	
A & C				0.003	
A & B				0.01	
Ferritin on day 14	398.5±31.43	637.37±436	519.8±431	0.293	
B & C				NA	
A & C				NA	
A & B				NA	
Ferritin on day 28		1355±896.3	410±0	0.157	
B & C				NA	
PaO2/FiO2 on day 3	298.57±211.3	154.14±138.9	166.9±130	0	
B & C				0.478	
A & C				0	
A & B				0	
PaO2/FiO2 on day 7	320.62±93.64	163.55±172.6	178.5±138	0	
B & C				0.413	
A & C				0	
A & B				0	
PaO2/FiO2 on day 14	389.75±51.93	154.67±174	165.2±98.87	0.005	
B & C				0.155	
A & C				0.022	
A & B				0.001	
PaO2/FiO2 on day 28		172.75±181	53±0	0.48	
B & C				NA	
GCS	3	0	3	6	0

on day 3	4	0	1	0	
	6	0	1	0	
	7	0	0	1	
	8	0	0	1	
	9	0	0	1	
	10	0	2	10	
	12	0	0	1	
	13	1	0	3	
	14	1	5	6	
	15	51	94	77	
B & C					0.002
A & C					0
A & B					0.213
GCS on day 7	3	0	10	13	0
	6	0	1	1	
	7	0	0	1	
	9	0	0	1	
	10	0	3	11	
	12	0	0	1	
	13	0	1	1	
	14	0	3	3	
	15	39	66	42	
B & C					0.003
A & C					0
A & B					0.011
GCS on day 14	3	0	6	4	0.189
	10	0	0	3	
	13	0	1	0	
	14	0	1	2	
	15	4	11	7	
B & C					NA
A & C					NA
A & B					NA
GCS on day 28	3	0	2	1	0.414
	15	0	2	0	
B & C					NA

SOF A on day 3	0	12	1	1	0
	1	3	8	6	
	2	12	12	8	
	3	18	24	16	
	4	6	40	18	
	5	0	4	16	
	6	0	5	11	
	7	1	4	12	
	8	0	4	3	
	9	0	1	7	
	10	0	0	1	
	11	0	0	3	
	12	0	2	1	
	13	0	1	2	
	16	0	0	1	
	B & C				
A & C				0	
A & B				0	
SOF A on day 7	0	5	1	1	0
	1	18	4	4	
	2	12	10	10	
	3	3	13	13	
	4	0	28	7	
	5	1	7	7	
	6	0	6	5	
	7	0	2	6	
	8	0	1	4	
	9	0	2	2	
	10	0	4	2	
	11	0	3	3	
	12	0	0	3	
	13	0	1	2	
	14	0	1	2	
	15	0	1	2	
16	0	0	1		
B & C				0.256	
A & C				0	
A & B				0	

SOF A on day 14	0	3	1	0	0.008	
	1	1	1	1		
	2	0	1	1		
	3	0	2	3		
	4	0	4	3		
	5	0	4	2		
	6	0	0	1		
	8	0	2	2		
	9	0	1	1		
	11	0	2	0		
	12	0	0	1		
	14	0	1	0		
	16	0	0	1		
	B & C					0.797
	A & C					0.003
	A & B					0.004
SOF A on day 28	0	0	1	0	0.157	
	3	0	1	0		
	12	0	1	0		
	13	0	1	0		
17	0	0	1			
B & C				NA		
WH O scale on day 3	3	0	1	0	0	
	4	25	17	17		
	5	20	57	58		
	6	7	28	22		
	8	0	0	5		
	9	0	2	4		
	10	0	1	0		
B & C				0.758		
A & C				0		
A & B				0		
WHO scale on day 7	4	28	20	21	0	
	5	11	28	22		
	6	0	26	16		
	8	0	3	5		
	9	0	7	4		

	10	0	0	6	
B & C					0.982
A & C					0
A & B					0
WHO scale on day 14	4	4	2	7	0.015
	5	0	8	4	
	6	0	3	1	
	8	0	3	1	
	9	0	3	3	
B & C					0.136
A & C					0.062
A & B					0.005
WHO scale on day 28	5	0	2	0	0.136
	9	0	2	0	
	10	0	0	1	
B & C					NA
28-day mortality	Dead	1/53	34/106	43/106	0
	Alive	52/53	72/106	63/106	
B & C					0.176
A & C					0
A & B					0
Day of death		0.19±1.061	12.57±6.22	10.13±6.530	0
B & C					0.234
A & C					0
A & B					0
Mortality at discharge	Dead	1/53	33/106	41/106	0
	Alive	52/53	73/106	65/106	
B & C					0.223
A & C					0
A & B					0

PCR at hospital discharge	Positive	36/53	92/106	78/106	0.011
	Negative	17/53	14/106	28/106	
B & C					0.021
A & C					0.42
A & B					0.007
Incidence of serious adverse effect	Yes	0/53	0/106	0/106	1
	No	53/53	106/106	106/106	
B & C					NA
A & C					NA
A & B					NA
Incidence of AKI	Yes	1/53	4/106	7/106	0.36
	No	52/53	102/106	99/106	
B & C					NA
A & C					NA
A & B					NA
Incidence of ALD	Yes	1/53	6/106	3/106	0.404
	No	52/53	100/106	103/106	
B & C					NA
A & C					NA
A & B					NA
Need for IMV	Yes	1/53	22/106	22/106	0.005
	No	52/53	84/106	84/106	
B & C					1

A & C				0.003
A & B				0.003
Duration of need for O2 therapy and IMV	3.72±3.527	9.2±7.107	7.46±5.077	0
B & C				0.119
A & C				0
A & B				0
Time to clinical improvement	7.4±3.101	8.33±6.38	7.75±4.265	0.933
B & C				NA
A & C				NA

A & B				NA
Duration of hospital stay	8.94±3.165	11.85±6.264	10.59±5.26	0.011
B & C				0.054
A & C				0.185
A & B				0.004
Duration of ICU stay	1.45±1.835	7.6±7.614	6.69±6.23	0
B & C				0.51
A & C				0
A & B				0

8.2.1. effect of interventions on liver function

there is a statistically non-significant difference between the three groups in liver function tests (AST, ALT, bilirubin) after using the three antivirals with no significant hepatotoxicity in each group.

there is only a statistically significant difference in ALT in day 14 between B-C and in bilirubin in day 7 with albumin in day 14 between A-B & A-C while albumin in day 3,7 between A-C.




Figure 24: Distribution of ALT at day 14 across the three groups




Figure 25: Distribution of Bilirubin at day 7 across the three groups






Figure 26: Distribution of Albumin at day 3 across the three groups

Figure 28: Distribution of Albumin at day 14 across the three groups



8.2.2. effect of interventions on platelet counts

there is only a statistically significant difference between A-C & B-C in platelet count in day 3,7 and there are no other statistically significant differences between groups observed.




Figure 27: Distribution of Albumin at day 7 across the three groups

Figure 29: Distribution of platelets at day 3 across the three groups




Figure 30: Distribution of platelets at day 7 across the three groups

8.2.3. effect of interventions on kidney function

there is a statistically significant difference in serum creatinine between A-C & B-C in day 3,7 and between B-C in day 14 and there are no other statistically significant differences between groups observed.




Figure 31: Distribution of S.Cr at day 3 across the three groups




Figure 32: Distribution of S.Cr at day 7 across the three groups




Figure 33: Distribution of S.Cr at day 14 across the three groups

8.2.4. effect on inflammatory markers (CRP, D-dimer, CK, LDH, Ferritin)

There is only a statistically significant difference in CRP at day 3, D-dimer, LDH and ferritin at day 7 between A-B & A-C, LDH in day 3 between A-B.




Figure 34: Distribution of CRP at day 3 across the three groups




Figure 35: Distribution of CRP at day 7 across the three groups




Figure 36: Distribution of D-dimer at day 7 across the three groups




Figure 37: Distribution of CK at day 7 across the three groups





Figure 38: Distribution of LDH at day 3 across the three groups

Figure 40: Frequency of CRP at day 3 across the three groups





Figure 39: Distribution of LDH at day 7 across the three groups

Figure 41: Frequency of CRP at day 7 across the three groups




Figure 42: Frequency of D-dimer at day 7 across the three groups

8.2.5. effect on consciousness level

There is a statistically significant difference in GCS in day 3 between A-C & B-C and in day 7 between the three Groups and there are no other statistically significant differences between groups observed.




Figure 43: Distribution of GCS at day 3 across the three groups




Figure 44: Distribution of GCS at day 7 across the three groups

8.2.6. effect on score of multi-organ functions

There is a statistically significant difference in SOFA score in day 3 between the three group and in day 7,14 between A-B & A-C and there are no other statistically significant differences between groups observed.




Figure 45: Distribution of SOFA at day 3 across the three groups




Figure 46: Frequency of SOFA score at day 3 across the three groups




Figure 48: Frequency of SOFA score at day 7 across the three groups




Figure 47: Distribution of SOFA at day 7 across the three groups




Figure 49: Distribution of SOFA at day 14 across the three groups




Figure 50: Frequency of SOFA score at day 14 across the three groups

8.2.7. effect on oxygen pressure in blood

There is a statistically significant difference in PaO₂/FiO₂ in day 3,7,14 between A-B & A-C.




Figure 52: Distribution of PaO₂/FiO₂ at day 7 across the three groups




Figure 51: Distribution of PaO₂/FiO₂ at day 3 across the three groups




Figure 53: Distribution of PaO₂/FiO₂ at day 14 across the three groups

8.2.8. effect on 28-day mortality (primary outcome)

There is a statistically significant difference in 28-day mortality between A-B & A-C.





Figure 54: Distribution of 28-day mortality across the three groups

Figure 56: Distribution of mortality at discharge across the three groups

8.2.9. day of death in cases of mortality

There is a statistically significant difference in day of death between A-B & A-C.

8.2.11. PCR result at hospital discharge (primary outcome)

There is a statistically significant difference in swab PCR result between A-B & B-C.





Figure 55: Distribution of day of death across the three groups

Figure 57: Distribution of PCR results at discharge across the three groups

8.2.10. mortality at discharge

There is a statistically significant difference in death at discharge between A-B & A-C.




Figure 58: Frequency of PCR results at discharge across the three groups

8.2.12. incidence of any serious adverse effect leading to drug discontinuation (primary outcome)

There is a statistically non-significant difference between the three groups in causing of any serious adverse effect.




Figure 59: Distribution of serious adverse event incidence across the three groups

8.2.13. incidence of acute kidney injury (AKI) and acute liver damage (ALD)

There is a statistically non-significant difference between the three groups in causing any deterioration on kidneys or liver functions.




Figure 60: Distribution of AKI incidence across the three groups




Figure 61: Frequency of AKI incidence across the three groups




Figure 62: Frequency of ALD incidence across the three groups




Figure 63: Distribution of ALD incidence across the three groups

8.2.14. need for IMV during hospitalization

There is a statistically significant difference in need for IMV between A-B & A-C.




Figure 64: Distribution of IMV need across the three groups




Figure 65: Frequency of IMV need across the three groups

8.2.15. effect on number of days in which there is need for IMV or O2 therapy

There is a statistically significant difference in number of days with need for IMV or oxygen therapy between A-B & A-C.




Figure 66: Distribution of O2 therapy and IMV need duration across the three groups




Figure 67: Frequency of O2 therapy and IMV need duration across the three groups

8.2.16. effect on time to clinical improvement in days

There is a statistically non-significant difference between the three groups in time to clinical improvement in days




Figure 68: Distribution of Time to clinical improvement across the three groups

8.2.17. effect on hospital stay duration

There is a statistically significant difference in duration of hospitalization between A-B.




Figure 69: Distribution of hospital stay duration across the three groups




Figure 70: Frequency of hospital stay duration across the three groups

8.2.18. effect on ICU stay duration

There is a statistically significant difference in duration of ICU stay between A-B & A-C.




Figure 72: Frequency of ICU stay duration across the three groups

8.2.19. effect on WHO scale for COVID cases

There is a statistically significant difference in WHO scale in day 3,7 between A-B & A-C and in day 14 between A-B only.




Figure 71: Distribution of ICU stay duration across the three groups




Figure 73: Distribution of WHO score at day 3 across the three groups





Figure 74: Frequency of WHO score at day 3 across the three groups

Figure 76: Frequency of WHO score at day 7 across the three groups





Figure 75: Distribution of WHO score at day 7 across the three groups

Figure 77: Distribution of WHO score at day 14 across the three groups




Figure 78: Frequency of WHO score at day 14 across the three groups

For more statistical analysis that is performed on clinical data of this study, this is a link to a SPSS output file that contains all statistical analysis of the study. an excel data sheet and a SPSS data file containing all clinical data of the cases of the three groups can be found in this link in addition to an excel data sheet for included and excluded cases with date:

<https://drive.google.com/drive/folders/1X1dDQwW9vBvusutwMbeebUjN8jJqYxsh?usp=sharing>

IX. DISSCUSSION

9.1. Regarding baseline characteristics

9.1.1. Age

The age in groups A & B is statistically significant less than that in group C.

9.1.2. Gender

There is statistically significant more females in group B group than group C.

9.1.3. Number of comorbidities

There is statistically significant a greater number of comorbidities in group C than Group B.

9.1.4. Severity of COVID-19

There are statistically significant less severe cases in group A than groups B & C.

9.1.5. WHO clinical progression scale

The who scale is statistically significantly lower in group A than groups B & C.

9.1.6. Number of symptoms

There is statistically significant a smaller number of symptoms in group A than in groups B & C.

9.1.7. Antibiotics use

Although a statistically non-significant difference exists between the three groups in antibiotics use generally, the use of macrolide antibiotics is statistically significant more in group A group than group C.

9.1.8. Antiplatelet use

Use of antiplatelet (aspirin) is statistically significant more in group A group than group C.

9.1.9. Steroids use

The use of steroids is statistically significant more in group B than group A.

9.1.10. Additive therapy use

Use of paracetamol is statistically significant more in group C than group A and use of zinc is statistically significant more in group A than groups B & C.

9.1.11. Oxygen therapy use

In general, use of O2 therapy in group A is statistically significant less than groups B & C and O2 therapy using SFM, NIV, IMV in Group A is statistically significant less than Groups B & C, while the use of mask reservoir (MR) as O2 source is more in group B than group C.

9.1.12. Vasopressor use

Use of vasopressors in group A is statistically significant less than groups B & C.

9.1.13. Oxygen saturation

There is statistically significant more cases in group A who does not need O2 therapy with statistically significant higher O2 saturation on room air than groups B & C.

9.1.14. Coagulation profile

PT and INR in group A are statistically significantly less than that in groups B & C.

9.1.15. Kidney function test

Serum creatinine is statistically significantly higher in group C than groups A & B.

9.1.16. Inflammatory markers

D-dimer is statistically significantly higher in group A followed by group C followed by group B, $A > C > B$.

9.1.17. Blood picture

TLC is statistically significantly higher in group C than group B and hematocrit is statistically significantly higher in group A group than groups B & C.

9.1.18. Electrolytes

The potassium level is statistically significantly higher in group C than group B.

9.1.19. Blood gases

PaO₂ and PaO₂/FiO₂ are statistically significantly higher in value in group A than group B and PaO₂ is statistically significant higher in value in group A than group C.

9.1.20. Consciousness level

The consciousness level (GCS) is statistically significantly lower in group C than groups A & B.

9.1.21. Multi-Organ Functions Assessment

SOFA score is higher in group C than groups A & B and in group B than group A. $A > B > C$ in multi-organ functions (better multi-organ functions in A than B and B than C)

9.2. Regression analysis

After statistical analysis of baseline characteristics of the cases of the three groups and finding that statistically significant differences in some baseline characteristics exist between the three groups. Differences exist between age, gender, number of symptoms, number of co-morbidities, severity of COVID, WHO clinical progression scale, SOFA score, use of antiplatelets, & steroid, & zinc, serum creatinine, PT, INR, TLC, D-dimer, PaO₂, PaO₂/FiO₂ and use of O₂ therapy including IMV and NIV.

So, it is necessary to exclude the effect of these variables on the outcomes of the study which represented by the primary outcome and mainly 28-day mortality. For this reason, regression analysis is performed to explore the effects of these variables on the primary outcome of the study (28-day mortality).

After regression analysis, it is found that all baseline characteristics that differ between the three groups have no effect on the study outcome with exception of need for NIV and IMV, PaO₂ and PaO₂/FiO₂ that show effect on 28-day mortality. This is explained by the need for NIV & IMV and a decline in PaO₂ and PaO₂/FiO₂ can cause an increase in 28-day mortality.

9.3. Regarding outcomes of the study after intervention in the three groups

9.3.1. effect of interventions on liver function

ALT level is statistically significant higher in group C than group B, bilirubin at day 7 is lower in group A than groups B & C. Albumin in day 14 is higher in group A than groups B & C. while albumin at day 3,7 is higher in group A than group C. From these results, it is concluded that A causes less hepatic

damage than B & C.

9.3.2. effect of interventions on platelet counts

Platelets count at day 3,7 is statistically significantly lower in group C than groups A & B.

9.3.3. effect of interventions on kidney function

Serum creatinine at day 3,7 level is statistically significant higher in group C than groups A & B and at day 14 is higher in group C than group B.

9.3.4. effect on inflammatory markers (CRP, D-dimer, CK, LDH, Ferritin)

CRP at day 3,7 and D-dimer LDH & ferritin at day 7 are statistically significant lower in group A than groups B & C. LDH at day 3 is statistically significant lower in group A than group B.

From these results, it is concluded that inflammatory marker levels have been lowered by A than B & C interventions.

9.3.5. effect on consciousness level

GCS at day 3 is statistically significant lower in C than groups A & B, while GCS at day 7 is statistically significant higher in group A than groups B & C and in group B than group C ($A > B > C$).

9.3.6. effect on score of multi-organ functions

SOFA score at day 3 is statistically significant higher in group C than groups A & B and in group B than group A, SOFA score at day 7,14 is statistically significant lower in group A than groups B & C.

From these results, it is concluded that the best multi-organ functions are in this arrangement ($A > B > C$) with group A has the best multi-organ functions (lowest SOFA score).

9.3.7. effect on oxygen pressure in blood

PaO₂/FiO₂ value at day 3,7,14 is statistically significant higher in group A than groups B & C.

From these results, it is concluded that group A has more favorable oxygen level in blood than groups B & C.

9.3.8. effect on mortality at day 28 (primary outcome)

Group A has statistically significant lower 28-day mortality rate than groups B & C.

9.3.10. day of death in cases of mortality

Day of death is statistically significant less in group A than Groups B & C.

9.3.11. mortality at discharge

In addition to lower 28-day mortality, a statistically significant lower mortality rate at hospital discharge with group A than groups B & C.

9.3.12. PCR result at hospital discharge (primary outcome)

Group B has a statistically significant greater number of positive cases at discharge than groups A & C and group C has more positive cases than group A which has the highest number

of negative cases at discharge followed by group C followed by group B.

9.3.13. incidence of any serious adverse effect leading to drug discontinuation (primary outcome)

All three interventions have no significant adverse effect that proves their safety.

9.3.14. incidence of AKI and hepatotoxicity

No nephrotoxicity or hepatotoxicity observed with all three interventions that prove their safety.

9.3.15. need for invasive mechanical ventilation (IMV) during hospitalization

Group A has a statistically significantly lower need for IMV than groups B & C.

9.3.16. effect on number of days in which there is need for IMV or oxygen therapy

Group A has statistically significantly less duration with need for O₂ therapy or IMV than groups B & C.

9.3.17. effect on time to clinical improvement in days

A statistically non-significant difference exists between the three groups in time to clinical improvement in days.

9.3.18. effect on hospital stay duration

Group A has statistically significantly less duration of hospitalization than group B.

9.3.19. effect on ICU stay duration

Group A has statistically significant less duration of ICU stays than Groups B & C.

9.3.20. effect on WHO scale for COVID cases

Group A has statistically significant lower WHO progression scale than Groups B & C at day 3,7 and statistically significant lower WHO progression scale than Group B at day 14 that proves that less progression of the cases in Group A (lower WHO scale) than Groups B & C.

X. CONCLUSION

Casirivimab and imdevimab group achieves less 28-day mortality rate, less mortality at hospital discharge, more negative swab cases, less need for O₂ therapy and IMV, less duration of this need, less hospital and ICU stay, less case progression as presented by lower WHO scale and better multi-organ functions as presented by lower SOFA score than Remdesivir and Favipravir groups.

From all of these results, it is concluded that group A (Casirivimab & imdevimab) has more favorable clinical outcomes than groups B (remdesivir) & C (favipravir).

XI. REFERENCES

Aleem, A. & Kothadia, J. P., 2021. Remdesivir. Stat Pearls. Treasure Island (FL): Stat Pearls Publishing Copyright © 2021, Stat Pearls Publishing LLC.

Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., Wei, Y., Atwal, G. S., Murphy, A. J., Stahl, N., Yancopoulos, G. D. & Kyratsous, C. A., 2020. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science*, 369, 1014-1018.

De Almeida, S. M. V., Santos Soares, J. C Dos Santos, K. L., Alves, J. E. F., Ribeiro, A. G., Jacob Í, T. T., Da Silva Ferreira, C. J., Dos Santos, J. C., De Oliveira, J. F., De Carvalho Junior, L. B. & De Lima, M., 2020. COVID-19 therapy: What weapons do we bring into battle? *Bioorg Med Chem* 28, 115757

Food And Drug Administration (FDA), 2021. Emergency Use Authorization (EUA) Of Regen-Cov (casirivimab and imdevimab. Available [Online].: <https://www.fda.gov/media/145611/download> [Accessed 13/10/2021]).

Garibaldi, B. T., Wang, K., Robinson, M. L., Zeger, S. L., Bandeen-roche, K., Wang, M. C., Alexander, G. C., Gupta, A., Bollinger, R. & Xu, Y. 2021. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. *JAMA Netw Open*, 4, e213071.

Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., Chung, K. M., Hermann, A., Ullman, E., Cruz, J., Rafique, A., Huang, T., Fairhurst, J., Libertiny, C., Malbec, M., Lee, W.-Y., Welsh, R., Farr, G., Pennington, S., Deshpande, D., Cheng, J., Watty, A., Bouffard, P., Babb, R., Levenkova, N., Chen, C., Zhang, B., Hernandez, A. R., Saotome, K., Zhou, Y., Franklin, M., Sivapalasingam, S., Lye, D. C., Weston, S., Logue, J., Haupt, R., Frieman, M., Chen, G., Olson, W., Murphy, A. J., Stahl, N., Yancopoulos, G. D. & Kyratsous, C. A., 2020. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science*, 369, 1010-1014.

National Institute of Health (NIH), 2021. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines Available [Online].: <https://www.covid19treatmentguidelines.nih.gov/>

, Okonji, E. F., Okonji, O. C., Mukumbang, F. C. & Van Wyk B., 2021. Understanding varying COVID-19 mortality rates

reported in Africa compared to Europe, Americas and Asia. *Trop Med Int Health*, 26, 716-719.

Owji, H., Negahdaripour, M. & Hajighahramani, N., 2020. Immunotherapeutic approaches to curtail COVID-19 *Int Immunopharmacol*, 88, 106924.

Plaçais, L., Richier, Q., Noël, N., Lacombe, K., Mariette, X. & Hermine, O. 2022. Immune interventions in COVID-19: a matter of time? *Mucosal Immunology*, 15, 198-210.

Umakanthan, S., Chattu, V. K., Ranade, A. V., Das, D., Basavarajegowda, A. & Bukelo, M., 2021. A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19. *AIMS Public Health*, 8, 137-153

Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., Perry, C., Pan, C., Hosain, R., Mahmood, A., Davis, J. D., Turner, K. C., Hooper, A. T., Hamilton, J. D., Baum, A., Kyratsous, C. A., Kim, Y., Cook, A., Kampman, W., Kohli, A., Sachdeva, Y., Graber, X., Kowal, B., Dicioccio, T., Stahl, N., Lipsich, L., Braunstein, N., Herman, G. & Yancopoulos, G. D., 2020. REGN-COV2, a Neutralizing Antibody Cocktail, in

Outpatients with Covid-19. *New England Journal of Medicine*, 384, 238-251

Yang, Z., Hu, Q., Huang, F., Xiong, S. & Sun, Y. 2021 The prognostic value of the SOFA score in patients with COVID-19 A retrospective, observational study. *Medicine (Baltimore)*, 100, e26900

XII. AUTHORS

First Author – Ahmed H. Hassan, Clinical Pharmacist, Mansoura University Hospital

Second Author – Sahar K. Hegazy, Professor and Head of Clinical pharmacy Department, Faculty of Pharmacy, Tanta University

Third Author – Samar T. Radwan, Assistant professor of Rheumatology and Immunology, Faculty of Medicine, Mansoura University

Correspondence Author – Ahmed H. Hassan, ahmedony26@gmail.com, 2001554658010, 2001155848245